MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:37Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Retinoids]]
			[[Category:Topical retinoids]]
			[[Category:Antineoplastics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #197

2026-05-23T04:00:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #197

New page

{{MedTemplate
| generic = Tretinoin (all-trans retinoic acid, ATRA)
| brand = Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL)
| structure =
| classes = [[:Category:Retinoids|Retinoid]], [[:Category:Topical_retinoids|Topical retinoid]], [[:Category:Antineoplastics|Antineoplastic (oral, APL)]]
| uses = <vote slug="acne-vulgaris-use">Acne vulgaris (topical)</vote>, <vote slug="photoaging-use">Photoaging</vote>, <vote slug="apl-use">Acute promyelocytic leukemia (oral ATRA, with arsenic trioxide or anthracycline)</vote>
| starting_dose = Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses
| preparations = Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid)
| fda_max = Topical: nightly; oral APL: 45 mg/m²/d
| pill_id =
| routes = Topical, oral (APL only)
| onset = Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days
| duration = N/A
| halflife = ~0.5-2 hours (oral)<ref name="vesanoid-label">FDA Prescribing Information, Vesanoid (tretinoin), Roche, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020438s004lbl.pdf</ref>
| bioavailability = Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing<ref name="vesanoid-label" />
| pregnancy = '''Oral tretinoin is teratogenic''' (Category D historically; APL exception treated under strict pregnancy avoidance); topical tretinoin in pregnancy has lower (but not zero) concern and is generally avoided.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="tretinoin-mech-claim">Tretinoin is all-trans retinoic acid, the active metabolite of vitamin A; it binds nuclear retinoic acid receptors (RAR α/β/γ), regulating transcription of genes governing epithelial differentiation, proliferation, and inflammation.</vote> In acne, normalizes follicular keratinization and reduces comedone formation. In APL, the PML-RARα fusion oncoprotein responds to pharmacologic ATRA by resuming terminal granulocytic differentiation — one of the first successful examples of differentiation therapy in oncology, transforming APL from highly fatal to highly curable. Differentiation syndrome (capillary leak, hyperleukocytosis, dyspnea) is the major adverse effect of oral APL induction<ref name="vesanoid-label" />.
}}

== References ==
<references />

Tretinoin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #197